23.50

1.59% -0.38

After Hours: 22.15 -1.35 -5.74%

Ultragenyx Pharmaceutical Inc (RARE)

Overview News Price History Option Chain Financials Why RARE Down? Discussions Forecast Stock Split

Ultragenyx Pharmaceutical Inc stock is traded at $23.50, with a volume of 1.88M. It is down -1.59% in the last 24 hours and down -3.57% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Previous Close:

$23.88

Open:

$23.96

24h Volume:

1.88M

Relative Volume:

0.79

Market Cap:

$2.27B

Revenue:

$610.16M

Net Income/Loss:

$-532.93M

P/E Ratio:

-4.2505

EPS:

-5.5287

Net Cash Flow:

$-442.30M

1W Performance:

-1.22%

1M Performance:

-3.57%

6M Performance:

-16.40%

1Y Performance:

-45.89%

1-Day Range:

$22.93

$24.35

1-Week Range:

$22.93

$24.87

52-Week Range:

$18.41

$46.27

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name

Ultragenyx Pharmaceutical Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

415-483-8800

Address

60 LEVERONI COURT, NOVATO, CA

Employee

1,294

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RARE Ultragenyx Pharmaceutical Inc	23.50	2.30B	610.16M	-532.93M	-442.30M	-5.5287
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Jul-28-25	Resumed	H.C. Wainwright	Buy
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy
Apr-22-24	Initiated	RBC Capital Mkts	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jun-14-23	Resumed	Credit Suisse	Outperform
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight
Jan-18-23	Resumed	Canaccord Genuity	Buy
Dec-30-22	Resumed	H.C. Wainwright	Buy
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight
Sep-30-21	Initiated	H.C. Wainwright	Buy
Aug-19-21	Initiated	UBS	Sell
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
May-06-21	Upgrade	Citigroup	Neutral → Buy
May-06-21	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-02-21	Resumed	Stifel	Buy
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-07-20	Downgrade	Wedbush	Outperform → Neutral
Nov-24-20	Resumed	Evercore ISI	In-line
Nov-12-20	Downgrade	BofA Securities	Buy → Neutral
Aug-02-19	Resumed	Wedbush	Outperform
Mar-27-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-22-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-08-18	Upgrade	Citigroup	Sell → Neutral
Sep-10-18	Initiated	Morgan Stanley	Equal-Weight
Jun-21-18	Downgrade	Credit Suisse	Outperform → Neutral
May-11-18	Upgrade	Barclays	Equal Weight → Overweight
May-10-18	Initiated	Goldman	Neutral
Apr-18-18	Upgrade	SunTrust	Hold → Buy
Mar-22-18	Resumed	Piper Jaffray	Overweight
Feb-21-18	Reiterated	Stifel	Buy
Jan-22-18	Upgrade	Evercore ISI	In-line → Outperform
Jan-18-18	Initiated	Credit Suisse	Outperform
Dec-05-17	Reiterated	Barclays	Equal Weight
Dec-04-17	Upgrade	Jefferies	Hold → Buy
Sep-14-17	Upgrade	Wedbush	Neutral → Outperform

View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

08:18 AM

Ultragenyx Pharmaceutical Q4 Earnings Call Highlights - MarketBeat

08:18 AM

06:51 AM

Earnings call transcript: Ultragenyx Q4 2025 sees revenue growth, stock dips - Investing.com

06:51 AM

06:42 AM

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire

06:42 AM

06:00 AM

Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada

06:00 AM

05:15 AM

Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q4 EPS -$1.29, vs. FactSet Est of -$1.09 - marketscreener.com

05:15 AM

Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Australia

05:15 AM

05:13 AM

Ultragenyx (RARE) Revenue Forecasts Highlight Crysvita and Dojolvi Growth - GuruFocus

05:13 AM

05:11 AM

Ultragenyx Pharmaceutical Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts - marketscreener.com

05:11 AM

Ultragenyx shares fall as 2026 revenue guidance misses expectations - Investing.com

05:11 AM

Ultragenyx shares fall as 2026 revenue guidance misses expectations By Investing.com - Investing.com India

05:11 AM

05:00 AM

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update - The Manila Times

04:20 AM

04:04 AM

Ultragenyx Pharmaceutical Q4 Earnings Report: What Investors Need to Know - Benzinga

04:04 AM

03:00 AM

Investors in Ultragenyx Pharmaceutical Inc. Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsRARE - PR Newswire

03:00 AM

01:09 AM

RARE Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE) - The Malaysian Reserve

01:09 AM

12:36 PM

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire

12:36 PM

11:51 AM

Ultragenyx earnings in focus as gene therapy hopes offset drug flop - Investing.com Nigeria

11:51 AM

10:54 AM

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire

10:54 AM

12:27 PM

Ultragenyx: Fourth Quarter Financial Overview - Bitget

12:27 PM

Feb 11, 2026

Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical - Intellectia AI

Feb 11, 2026

Class Action Announcement for Ultragenyx Pharmaceutical - GlobeNewswire

Feb 11, 2026

Earnings Outlook For Ultragenyx Pharmaceutical - Benzinga

Feb 11, 2026

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

Feb 11, 2026

Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law - GlobeNewswire

Feb 11, 2026

RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - The Malaysian Reserve

Feb 11, 2026

Levi & Korsinsky Notifies Shareholders of Ultragenyx Pharmaceutical Inc.(RARE) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire

Feb 11, 2026